{"prompt": "['MC1575', '28', 'Amendment 2', 'concurrent direct', 'bilirubin elevations', '>2 X ULN', 'Mild indirect', 'hyperbilirubinemia,', 'known or suspected', 'Continue lenvatinib, but monitor weekly until ALT returns to Grade 1', \"Gilbert's syndrome,\", '(NCI CTCAE v4) or baseline', 'and elevation in', 'ALT: >3 X ULN', '8.35', 'Management of Other Adverse Events', 'CTCAE', 'Adverse', 'SOC', 'Event', 'Grade', 'Treatment Modification', 'Hold therapy if hemoptysis is in excess of 2.5 mL', 'Grade 1', '(1/2 teaspoon) per day until resolved, otherwise', 'maintain current dose.', 'Hold lenvatinib unless resolved to Grade 1; reduce', 'Respiratory,', 'Broncho-', 'dose to next lower dose level, and continue', 'thoracic and', 'treatment.', 'mediastinal', 'pulmonary', 'Grade 2', 'hemorrhage', 'If Grade 2 or greater hemorrhage/bleeding recur', 'disorders', 'following dose reduction, discontinue lenvatinib and', 'patient enters event monitoring phase', 'Grades 3 or 4', 'Discontinue lenvatinib and patient enters event', 'monitoring study phase', 'Grade 1', 'No interruption in treatment; maintain current dose', 'Hold lenvatinib until subject is receiving a stable', 'dose of Low Molecular Weight Heparin (LMWH).', 'Concurrent warfarin will not be allowed, if patient', 'needs warfarin, stop the study drug and enter event', 'monitoring.', 'Treatment may resume during the period of full-', 'dose anticoagulation if all of the following criteria', 'are met:', 'Vascular', 'Thrombo-', 'Grade 2, 3', 'The subject must be have been treated with an', 'disorders', 'embolic event', 'anticoagulant at the desired level for at least one', 'week', 'The subject must not have had a Grade 3 or 4 or', 'significant Grade 2 hemorrhagic event while on', 'anticoagulant', 'Subject should be monitored as clinically indicated', 'during anticoagulation treatment and after resuming', 'study treatment.', 'Grade 4', 'Discontinue lenvatinib and patient enters event', 'or pulmonary', 'monitoring', 'embolus', 'Protocol Version Date: :16Aug2018']['MC1575', '29', 'Amendment 2', '9.0', 'ANCILLARY TREATMENT/SUPPORTIVE CARE', '9.1', 'Full supportive care', 'Patients should receive full supportive care while on this study. This includes blood', 'product support, antibiotic treatment, and treatment of other newly diagnosed or', 'concurrent medical conditions. All blood products and concomitant medications such as', 'antidiarrheals, analgesics, and/or antiemetics received from the first day of study', 'treatment administration until 30 days after the final dose will be recorded in the medical', 'records.', '9.2', 'Blood products and growth factors', 'Blood products and growth factors should be utilized as clinically warranted and', 'following institutional policies and recommendations. The use of growth factors should', 'follow published guidelines of the Journal of Clinical Oncology, Vol 24, No 18 (June', '20), 2006: pp. 2932-2947.', '9.3', 'Antiemetics', 'Antiemetics may be used at the discretion of the attending physician.', '9.4', 'Diarrhea', 'Diarrhea could be managed conservatively with loperamide. The recommended dose of', 'loperamide is 4 mg at first onset, followed by 2 mg every 2-4 hours until diarrhea free', '(maximum 16 mg/day).', 'In the event of Grade 3 or 4 diarrhea, the following supportive measures are allowed:', 'hydration, octreotide, and antidiarrheals.', 'If diarrhea is severe (requiring intravenous rehydration) and/or associated with fever or', 'severe neutropenia (grade 3 or 4), broad-spectrum antibiotics must be prescribed. Patients', 'with severe diarrhea or any diarrhea associated with severe nausea or vomiting should be', 'hospitalized for intravenous hydration and correction of electrolyte imbalances.', '9.5', 'Hypertension', 'Please see Appendix IV for guidelines regarding management of hypertension. They', 'should be seen by an expert in management of hypertension before they are started on the', 'study drug. During the therapy patients will experience worsening of hypertension', 'especially the secretory tumors and repeat consultation with the expert in recommended', 'for concurrent management.', '9.6', 'Tumor lysis syndrome', 'Patients may experience tumor lysis-like syndrome if they get profound, rapid response', 'to therapy. Tumor lysis is characterized by hyperkalemia, hypocalcemia, elevated uric', 'acid, renal failure and ECG abnormalities. Please see Section 8.2 for dose modification.', 'If there are changes in the electrolytes they should be managed as per the Section 8.31. If', 'there is suspicion of tumor lysis or tumor lysis-like syndrome then therapy should be', 'held, Allopurinol 300 mg daily should be instituted. EKG, laboratory examination,', 'history and physical examination should be repeated in 1 week. If EKG and laboratory', 'values have normalized, and patient is clinically stable then therapy can be re-instituted.', '9.7', 'Precautions/Warnings', '9.71', 'Drug-Drug Interactions', 'There have been few completed human studies, at present, specifically evaluating', 'drug-drug interactions with lenvatinib. The weak inhibitory effect on CYP P450', 'Protocol Version Date:16Aug2018']\n\n###\n\n", "completion": "END"}